18:29 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Strongbridge's Cushing syndrome candidate meets in Phase III

Strongbridge Biopharma plc (NASDAQ:SBBP) said Recorlev levoketoconazole met the primary and secondary endpoints in the Phase III SONICS trial to treat endogenous Cushing syndrome. On the 94-patient trial's primary endpoint, 30% of patients achieved normalization of...
17:57 , Jul 20, 2018 |  BC Week In Review  |  Company News

Takeda, Ovid expand TAK-935 collaboration with three new trials

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Ovid Therapeutics Inc. (NASDAQ:OVID) expanded their collaboration for TAK-935 (OV935) to include three new trials in pediatric populations, including in two additional rare epilepsy syndromes. The partners expect to...
16:53 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

FDA approves J&J's Symtuza for HIV-1 infection in adults

FDA approved Symtuza darunavir/cobicistat/emtricitabine/tenofovir alafenamide from Johnson & Johnson (NYSE:JNJ) to treat HIV-1 infection in adults who have not previously received antiretroviral therapy (ART) or who have HIV-1 RNA levels of less than 50 copies/mL...
21:36 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Cell culture and mouse studies identified an inhibitor of M. tuberculosis cytochrome bc1 that could help treat tuberculosis (TB). Screening of small molecule library in M. tuberculosis culture and chemical synthesis of analogs of...
17:47 , Jun 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on 124 genomic loci could help predict the risk of myopia and other ocular refractive errors. Genome-wide association studies (GWAS) in 255,925 individuals identified associations between ocular refractive errors including myopia and...
18:19 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS In vitro and cell culture studies identified an allophenylnorstatine-tetrahydrofuranylglycine conjugate-based inhibitor of HIV protease that could help treat protease inhibitor-resistant HIV infection. Chemical synthesis and in vitro activity assays of allophenylnorstatine-tetrahydrofuranylglycine conjugate analogs yielded...
22:47 , Jun 5, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Cell models A neural network chip and an accompanying microinjection unit could be used to study retinal development and degeneration. The chip was generated by fabricating a device containing over 20,000 microwells arranged in a...
18:57 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro, cell culture and mouse studies suggest inhibiting the DNAJ/Hsp70 chaperone axis could help treat castration-resistant prostate cancer (CRPC). Screening of a library of chalcone analogs and testing in cell-based signaling assays...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing fibroblast...
22:43 , Apr 10, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Biosynthesis A liver microsome-based biosynthesis method could be used to generate multiple analogs of drug compounds. The method involves four steps: generating preparations of liver microsomes from eight mammalian species (mouse, rat, hamster, guinea pig,...